OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602
News Jun 24, 2008
OSI Pharmaceuticals, Inc. has announced that it has initiated the first-in-human clinical study of its development compound PSN602. Discovered by OSI’s diabetes and obesity team, PSN602 is an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity. PSN602 is the first clinical candidate to emerge from the Company’s research efforts in obesity.
“Our research efforts are focused on designing innovative, next-generation, small molecule compounds to provide safer or more effective options for the treatment of type 2 diabetes and obesity,” stated Anker Lundemose, M.D., Ph.D., President of (OSI) Prosidion. “We believe that not only does PSN602 have the potential to have a favorable side-effect profile relative to current therapies for obesity, but also the potential to provide greater efficacy.”
The double-blind, placebo-controlled, ascending, single and multiple, oral dose study is designed to provide preliminary information on the safety, tolerability and pharmacokinetics of PSN602 in healthy lean and overweight/obese subjects, as well as on the effects of PSN602 on appetite and food intake in healthy overweight/obese subjects.